Biodexa Pharmaceuticals (BDRX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an extension to meet the $1.00 minimum bid price requirement. This development provides the company with additional time to stabilize its stock price, crucial for its continued Nasdaq listing. Investors will be watching closely as Biodexa works towards compliance by the end of October 2024.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.